Research programme: breast cancer therapy - BioFocus/Australian Cancer Technology
Alternative Names: Breast cancer therapy research programme - BioFocus/AustCancerLatest Information Update: 10 Apr 2014
At a glance
- Originator Avantogen; BioFocus DPI
- Class Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
- 23 Sep 2003 Discontinued - Preclinical for Breast cancer in Australia (unspecified route)
- 23 Sep 2003 Discontinued - Preclinical for Breast cancer in United Kingdom (unspecified route)